At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Canakinumabdrug
Likely dose
Canakinumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular Involvement
In Brief
A Phase 2 clinical trial evaluating Canakinumab for Behcet Disease. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBehcet Disease
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJun 2016
Primary CompletionJan 2019
TodayJul 2026
First PostedApr 29, 2016
Enrollment StartJun 23, 2016
Primary CompletionJan 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.2 years ago
Interventions
Canakinumabdrug
150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)